Open AccessComparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy
Author(s) -
Simone Krebs,
Joseph A. O’Donoghue,
Evan Biegel,
Bradley J. Beattie,
Diane Lauren Reidy,
Serge K. Lyashchenko,
Jason S. Lewis,
Lisa Bodei,
Wolfgang Weber,
Neeta PanditTaskar
Publication year - 2020
Publication title -
european journal of nuclear medicine and molecular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.313
H-Index - 163
eISSN - 1619-7089
pISSN - 1619-7070
DOI - 10.1007/s00259-020-04832-9
Subject(s) - radionuclide therapy , dota , medicine , nuclear medicine , neuroendocrine tumors , pet ct , positron emission tomography , radiology , in vivo , microbiology and biotechnology , biology
Paired imaging/therapy with radiolabeled somatostatin receptor (SSTR) antagonists is a novel approach in neuroendocrine tumors (NETs). The aim of this study was to compare tumor uptake of 68 Ga-DOTA-JR11 and 177 Lu-satoreotide tetraxetan ( 177 Lu-DOTA-JR11) in patients with NETs.